Krystal Biotech, Inc. Total Long-Term Debt
Krystal Biotech, Inc. (KRYS) had Total Long-Term Debt of $4.25 million as of 2017-08-08, per its 10-Q filed 2018-11-05.
Discontinued › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2018-11-05
- 2017-08-08: Long-term Debt $4.25M.
| Period end | Long-term Debt |
|---|---|
| 2017-08-08 | $4.25M 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |